The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells
Mediators of Inflammation · 2026-01 · 2026 (1)
DOI: 10.1155/mi/2632235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 25.04.2026. Verfasst von Yang Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Transplantation Surgery, Ludwig-Maximilians-University Munich, Munich, Bayern, Germany, uni-muenchen.de. Hauptthemen laut MEDLINE: Thrombospondin 1, Calcitriol, Pancreatic Neoplasms, Pancreatic Stellate Cells. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, National Natural Science Foundation of China, Projekt DEAL.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) exhibits pronounced desmoplasia, primarily attributed to the activation of pancreatic stellate cells (PSCs) from a quiescent state (quiescent PSCs [qPSCs]) to an activated form (activated PSCs [aPSCs]), which facilitates tumor progression and therapeutic resistance. This study investigates the potential of the vitamin D3 (VD) analog calcipotriol (Cal) to modulate this activation process and its impact on PDAC cell malignancy, with a particular focus on the thrombospondin 1/cluster of differentiation 47 (THBS1/CD47) signaling axis. Through analyzing VDR mRNA expression in aPSCs versus PDAC cells, we found that aPSCs are more responsive to VD signaling. Treatment with Cal significantly reduced aPSC activation, as evidenced by decreased α‐SMA expression and THBS1 secretion, thereby diminishing stromal support for PDAC cell proliferation, migration, and invasion. These changes were mediated by the inhibition of the THBS1/CD47 axis, highlighting a novel mechanism by which Cal disrupts the supportive tumor microenvironment. Our findings highlight the therapeutic potential of targeting aPSCs with VD analogs in PDAC, suggesting a new direction for treatments that aim to interrupt the desmoplastic reaction and thereby inhibit PDAC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General, Visceral and Transplantation Surgery, Ludwig-Maximilians-University Munich, Munich, Bayern, Germany, uni-muenchen.de.
- Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, njmu.edu.cn.
- The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China, njucm.edu.cn.
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Bayern, Germany, dkfz.de.
- Department of General, Visceral and Vascular Surgery, Agatharied Hospital, Hausham, Bayern, Germany.
ORCID-Profile: Yang Wu, Jan G D'Haese, Bernhard Renz
Förderung
- China Scholarship Council
- National Natural Science Foundation of China
- Projekt DEAL
Zitieren
APA
Wu, Y., Zhang, C., Ilmer, M., Weniger, M., Li, Q., Wang, J., Miksch, R. C., Werner, J., D'Haese, J. G., & Renz, B. (2026). The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/2632235
Vancouver
Wu Y, Zhang C, Ilmer M, Weniger M, Li Q, Wang J, et al. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/2632235
BibTeX
@article{Wu2026,
author = {Wu, Yang and Zhang, Chun and Ilmer, Matthias and Weniger, Maximilian and Li, Quan and Wang, Jing and Miksch, Rainer C and Werner, Jens and D'Haese, Jan G and Renz, Bernhard},
title = {The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells},
journal = {Mediators of Inflammation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/mi/2632235}
}
EUVIMED